

Transcranial direct current stimulation in the treatment of major depression: a meta-analysis

U. G. Kalu, C. E. Sexton, C. K. Loo and K. P. Ebmeier*

Department of Psychiatry, University of Oxford, Oxford, UK

Background. So far, no comprehensive answer has emerged to the question of whether transcranial direct current stimulation (tDCS) can make a clinically useful contribution to the treatment of major depression. We aim to present a systematic review and meta-analysis of tDCS in the treatment of depression.

Method. Medline and Embase were searched for open-label and randomized controlled trials of tDCS in depression using the expressions ('transcranial direct current stimulation' or 'tDCS') and ('depression' or 'depressed'). Study data were extracted with a standardized data sheet. For randomized controlled trials, effect size (Hedges' g) was calculated and the relationships between study variables and effect size explored using meta-regression.

Results. A total of 108 citations were screened and 10 studies included in the systematic review. Six randomized controlled trials were included in the meta-analysis, with a cumulative sample of 96 active and 80 sham tDCS courses. Active tDCS was found to be more effective than sham tDCS for the reduction of depression severity (Hedges' $g=0.743$, 95% confidence interval 0.21–1.27), although study results differed more than expected by chance ($Q=15.52$, $df=6$, $p=0.017$, $I^2=61.35$). Meta-regression did not reveal any significant correlations.

Conclusions. Our study was limited by the small number of studies included, which often had small sample size. Future studies should use larger, if possible representative, health service patient samples, and optimized protocols to evaluate the efficacy of tDCS in the treatment of depression further.

Received 23 November 2010; Revised 9 December 2011; Accepted 15 December 2011; First published online 12 January 2012

Key words: Depression, meta-analysis, review, transcranial direct current stimulation.

Introduction

Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimulation in which a relatively weak direct current is passed into the cerebral cortex through small scalp electrodes. This results in a modulation of cortical excitability and spontaneous neural activity, dependent upon the polarity of the stimulation (Bindman *et al.* 1964; Nitsche *et al.* 2009). Anodal tDCS enhances cortical excitability and resting membrane potential shifts towards depolarization, with increased rate of firing (i.e. neurons underlying the anode become 'excited'), whereas cathodal tDCS reduces cortical excitability and resting membrane potential shifts towards hyperpolarization, with a reduced rate of neuronal firing (i.e. neurons underlying the cathode become 'inhibited'). These effects have been shown to last for more than 1 h, given a sufficient duration of

stimulation (Nitsche & Paulus, 2000, 2001; Nitsche *et al.* 2003, 2009).

Because of its neuromodulatory effects, tDCS has been investigated as a treatment for neurological and psychiatric diseases. Attempts to explore the effects of tDCS on mood and depressive symptoms in humans have been made for several decades. However, the methodology and experimental protocols of currently performed studies differ fundamentally from those applied in the first studies in the 1960s (summarized in Supplementary Table S1, online).

Early studies aimed to stimulate the brainstem, and for this reason anodal electrodes were placed bi-frontally, as close as possible to the eyebrows. A reference electrode was positioned at the knee, and a relatively strong and long-lasting stimulation of up to 8 h per day for several days was performed (Costain *et al.* 1964; Lippold & Redfearn, 1964; Redfearn *et al.* 1964). Some open-label studies and clinical observations reported positive effects of tDCS in depression (Redfearn *et al.* 1964; Ramsay & Schlagenhauf, 1966; Baker, 1970; Carney *et al.* 1970; Nias & Shapiro, 1974). However, controlled trials failed to replicate these findings (Arfai *et al.* 1970), and a recent study by

* Address for correspondence: K. P. Ebmeier, M.D., Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, UK.

(Email: klaus.ebmeier@psych.ox.ac.uk)

Koenigs *et al.* (2009) could not replicate any mood-altering effects of tDCS in healthy subjects. These initial mixed findings, together with the development of psychotropic drugs, led to a decreased interest in tDCS as a treatment tool for major depression during the 1970s and 1980s.

Methodological improvements and the promising results of repetitive transcranial magnetic stimulation (rTMS) in depression led to a re-evaluation of the therapeutic application of tDCS. Based on the hypothesis that the left dorsolateral prefrontal cortex (DLPFC) is hypoactive in depression (Grimm *et al.* 2008), the common rationale of currently performed studies is to modify activity in the prefrontal cortex and to re-establish the balance of left and right prefrontal cortex activation (i.e. to enhance excitability of the left prefrontal and to reduce excitability of the right prefrontal cortex). Therefore, anodal stimulation on the left DLPFC is performed, with the return cathodal electrode typically placed over the contralateral DLPFC or supraorbital region. Stimulation parameters typically involve current strength of 1–2 mA and duration of stimulation of typically 20 min per session.

A series of both open-label studies and randomized controlled trials (RCTs) have recently been conducted with the anodal electrode placed over the left DLPFC and contemporary stimulation parameters. To review the available evidence in an objective fashion, we present a systematic review of open-label studies and RCTs of tDCS in the treatment of depression and a meta-analysis of the results of RCTs. The key questions we aim to address in the systematic review are:

- (1) Is active tDCS associated with a reduction in symptom severity?
- (2) What is the weighted mean and range of percentage change in symptom severity?
- (3) Is any reduction in symptom severity following active tDCS clinically relevant?
- (4) What is the weighted mean and range of percentage of responders and remitters following treatment?
- (5) Is the beneficial effect of active tDCS lasting?
- (6) How many studies report that the beneficial effects persist at 1-month follow-up?

The meta-analysis aims to answer:

- (1) Is active tDCS associated with a significant reduction in symptom severity compared with sham tDCS?
- (2) What is the pooled effect size of RCTs?
- (3) What possible predictors are there for treatment response? For example, what patient population responds best to tDCS? What are the optimal tDCS parameters for the treatment of depression?

- (4) Is meta-regression between effect size and baseline symptom severity, concurrent antidepressant use, current strength and the total number of sessions significant?

Method

Data sources

Open-label studies and RCTs of tDCS were identified by entering the search terms ('transcranial direct current stimulation' or 'tDCS') and ('depression' or 'depressed') into the search engines of Medline and Embase. The search was completed in May 2011, with a start date of 1 January 1998. The start date was chosen with reference to the year of the first study performed with contemporary stimulation parameters (Priori *et al.* 1998) and has also been employed in a review of adverse effects of tDCS (Brunoni *et al.* 2011a). Reference lists of included studies were searched for further studies.

Study selection

Titles and abstracts of identified citations were examined independently by two authors (U.G.K. and C.E.S.) and any disagreements were resolved by discussion and consensus. For a paper to be included in the systematic review, the study had to report on tDCS in the treatment of patients with unipolar or bipolar major depression, and provide original data of open-label or RCTs with depressive severity as the outcome measure. Studies published as journal articles and letters were included, but conference abstracts were excluded. Authors of conference abstracts that had not been subsequently published as a peer-reviewed article or letter were contacted to ascertain the status of their research, and studies accepted for publication included. If data were published repeatedly as a whole or in parts, the most inclusive publication was used.

For studies to be included in the meta-analysis, the following inclusion criteria had to be met: (1) studies had to be of a randomized parallel or cross-over design, with sham control; (2) both patients and raters had to be unaware of treatment condition; (3) study findings had to be reported using clinician-assessed severity measures [Hamilton Depression Rating Scale (HAMD) or Montgomery–Åsberg Depression Rating Scale (MADRS)], with percentage change in severity measure either available or possible to derive from the publication, or made available post-publication by authors. In cross-over trials, only data from the initial stage of the trial were used to avoid carry-over effects between trial stages.

Data extraction and analysis

For the systematic review, the following variables were recorded independently by two authors (U.G.K. and C.E.S.) in a structured fashion: (1) study design; (2) patient characteristics (including age, bipolar or unipolar diagnosis); (3) tDCS parameters (electrode placement, current strength, duration of stimulation frequency, number of treatment sessions); (4) results (percentage change in severity score, percentage of responders and remitters, whether any beneficial effect persisted at 1-month follow-up). Response was defined as a reduction in severity score by at least 50%. Remission was defined as a HAMD score ≤ 7 or MADRS score ≤ 10 . For the meta-analysis, the mean and standard deviation of the percentage change in severity measure before and after treatment was extracted or calculated. Again, any disagreements were resolved by discussion and consensus.

For the systematic review, weighted means for the percentage change in severity score, percentage of responders and percentage of remitters were calculated from available data. For the meta-analysis, the efficacy of tDCS was investigated by calculating random model effect sizes (Hedges' g) based on percentage change in depression scales in active and sham groups (Comprehensive Meta-Analysis 2.2.048; Biostat Inc., USA). The random-effects model was chosen *a priori*, as we wished to make an unconditional inference beyond included studies (Hedges & Vevea, 1998). Heterogeneity was assessed using Cochran's Q and I^2 , the percentage of the total variability due to between-studies variability (Higgins *et al.* 2003). Publication bias was evaluated using Begg and Mazumdar rank correlations (Begg & Mazumdar, 1994) and Egger's regression intercept test (Egger *et al.* 1997).

Fixed-effect regression with Hedges' g was performed with the baseline symptom severity, concurrent antidepressant use (yes/no, yes if any patient was reported to be concurrently receiving antidepressants), current strength and the total number of active tDCS sessions. For baseline symptom severity the HAMD was used. If a HAMD score was not available, it was converted from MADRS score or scaled from the 24-item HAMD score (Heo *et al.* 2007).

To obtain the most complete dataset possible, authors were contacted and asked to provide any missing data. For Palm *et al.* (2011) subgroups of 1 mA and 2 mA were entered as if they were separate studies in order to reduce heterogeneity within each study.

Results

Titles and abstracts of 108 identified citations were screened; a flow diagram of the identification and




Fig. 1. Identification and attrition of studies.

attrition of studies is provided in Fig. 1. A total of 10 studies were included in the systematic review and are outlined in Tables 1 and 2. Of the studies, four were open-label trials and six were RCTs. The meta-analysis included six studies and a total of 96 depressed patients randomized to active tDCS and 80 randomized to sham tDCS.

Is active tDCS associated with a reduction in symptom severity?

The weighted mean for percentage reduction of symptom severity with active tDCS was 28.9% (open-label 24.8%, RCT 32.3%), ranging from 14.6% [1 mA group of Palm *et al.* (2011)] to 60% (Fregni *et al.* 2006a).

Is any reduction in symptom severity following active tDCS clinically relevant?

The weighted mean for percentage of patients classified as responders after active tDCS was 19.8% (open-label 17.5%, RCT 21.8%), ranging from 0% [1 mA group of Palm *et al.* (2011)] to 80.0% (Fregni *et al.* 2006a).

Regarding the percentage of patients that reached remission following active tDCS, the weighted mean was 8.5% (open-label 10.0%, RCT 6.1%), ranging from 0% (Loo *et al.* 2010, 2012; Martin *et al.* 2011; Palm *et al.* 2011) to 23.8% (Boggio *et al.* 2008).

Is the beneficial effect of active tDCS lasting?

A 1-month follow-up was reported by four studies. Boggio *et al.* (2008), Brunoni *et al.* (2011b) and Ferrucci *et al.* (2009) all reported that beneficial effects persisted at 1-month follow-up. Furthermore, percentage reduction in severity score increased from 18% to 50% in Brunoni *et al.* (2011b). Percentage reduction in severity score also increased at 1-month follow-up in Loo *et al.* (2012), although it is important to note that participants in this study were offered at least 15 further

Table 1. Overview of tDCS studies in major depression – participant details and methods

Study	Group	n	Diagnosis (n)	Electrode placement		Electrode size, cm ²	Current, mA	Duration	Number of sessions
				Anode	Cathode				
Open-label studies									
Brunoni <i>et al.</i> (2011b)	Active	14	BP	L DLPFC	R DLPFC	35	2	20 min	Twice daily for 5 consecutive days
Dell'Osso <i>et al.</i> (2011)	Active	23	UP (15), BP (8)	L DLPFC	R DLPFC	32	2	20 min	Twice daily for 5 consecutive days
Ferrucci <i>et al.</i> (2009)	Active (severe)	19				35	2	20 min	
	Active (mild-moderate)	13	UP or BP	L DLPFC	R DLPFC				Twice daily for 5 consecutive days
Martin <i>et al.</i> (2011)	Active	11	UP (9), BP (2)	L DLPFC	R upper arm	35	2	20 min	Once daily for 20 consecutive weekdays
Randomized controlled trials									
Boggio <i>et al.</i> (2008)	Active (DLPFC)	21	UP	L DLPFC	R supraorbital	35	2	20 min	Once daily for 10 consecutive weekdays
	Sham	10	UP					30 s	
	Active (occipital)	9	UP					Occipital	
Fregni <i>et al.</i> (2006a)	Active	5	MD	L DLPFC	R supraorbital	35	1	20 min	Once daily for 5 alternate days
	Sham	5	MD					A few seconds	
Fregni <i>et al.</i> (2006b)	Active	9	UP	L DLPFC	R supraorbital	35	1	20 min	Once daily for 5 alternate days
	Sham	9	UP					5 s	
Loo <i>et al.</i> (2010)	Active	20 ^a	UP	L DLPFC	R supraorbital	35	1	20 min	Once daily, three times per week for five sessions in sham-controlled phase. All participants then continued with active tDCS for up to 10 sessions
	Sham	20 ^b	UP					30 s	
Loo <i>et al.</i> (2012)	Active	33 ^c	UP (27), BP (4)	L DLPFC	F8	35	2	20 min	Once daily for 15 consecutive weekdays. All participants then offered at least 15 further active sessions
	Sham	31 ^d	UP (25), BP (4)					30 s	
Palm <i>et al.</i> (2011)	Active (1 mA)	5	UP (4), BP (1)	L DLPFC	R supraorbital	35	1	20 min	Once daily for 10 consecutive weekdays. Followed by 2-week cross-over
	Sham	5	UP						
Palm <i>et al.</i> (2011)	Active (2 mA)	6	UP (5), BP (1)	L DLPFC	R supraorbital	35	2	20 min	Once daily for 10 consecutive weekdays. Followed by 2-week cross-over
	Sham	6	UP						

tDCS, Transcranial direct current stimulation; BP, bipolar; L, left; DLPFC, dorsolateral prefrontal cortex; R, right; UP, unipolar; MD, major depression.

^a 19 completed sham and open phases. ^b 16 completed sham phase, 15 completed open phase. ^c 31 completed sham phase. ^d 29 completed sham phase.

Table 2. Overview of tDCS studies in major depression – results

Study	Group	Measure	Mean percentage reduction (s.d.)	Percentage responders	Percentage remitters	Summary
Open-label studies						
Brunoni <i>et al.</i> (2011b)	Active	HAMD	18.0	28.6	21.4	Significant reduction in depressive symptoms. Effects persisted at 1-month follow-up
Dell'Osso <i>et al.</i> (2011)	Active	HAMD	25.6	17.4	13	Significant reduction in depressive symptoms. Effects persisted at 1-week follow-up
Ferrucci <i>et al.</i> (2009)	Active (severe)	HAMD	20.6 (27.3)	12.5	6.3	Significant reduction of depressive symptoms in patients with severe depression at 1-month follow-up
	Active (mild-moderate)					
Martin <i>et al.</i> (2011)	Active	MADRS	43.8 (21.3)	18.2	0	Significant reduction in depressive symptoms
Randomized controlled trials						
Boggio <i>et al.</i> (2008)	Active (DLPFC)	HAMD	40.4 (25.8)	38.1	23.8	Significant reduction of depressive symptoms in active DLPFC group, compared with occipital and sham groups. Effects persist at 1-month follow-up
	Sham		10.4 (36.6)	20.0	0	
	Active (occipital)		21.3 (12.9)	0	0	
Fregni <i>et al.</i> (2006a)	Active	HAMD	About 60.0 (26.8)	80.0	Not stated	Significant reduction in depressive symptoms in active, but not sham, group
	Sham		About 12.0 (11.2)	0		
Fregni <i>et al.</i> (2006b)	Active	HAMD	58.5 (20.4)	Not stated	Not stated	Significant reduction in depressive symptoms in active compared with sham group
	Sham		13.1 (23.4)			
Loo <i>et al.</i> (2010)	Active	MADRS	19.5 (20.0)	10.5	0	Significant reduction in depressive symptoms in both active and sham groups
	Sham	MADRS	19.2 (23.0)	18.8	12.5	
Loo <i>et al.</i> (2012)	Active	MADRS	28.4 (23)	12.9	0	Significant reduction in depressive symptoms in active compared with sham group. Effects persist at 1-month follow-up
	Sham		15.9 (24)	13.8	0	
Palm <i>et al.</i> (2011)	Active (1 mA)	HAMD	14.6 (11.0)	0	0	No significant difference in depressive symptoms in active compared with sham after randomized controlled trial or cross-over stages
	Sham		9.0 (16.8)	0	0	
Palm <i>et al.</i> (2011)	Active (2 mA)	HAMD	16.7 (18.6)	16.7	0	
	Sham		14.9 (21.0)	0	0	

tDCS, Transcranial direct current stimulation; s.d., standard deviation; HAMD, Hamilton Depression Rating Scale; MADRS, Montgomery-Åsberg Depression Rating Scale; DLPFC, dorsolateral prefrontal cortex.




Fig. 2. Forest plot of effect sizes (Hedges' g) for active versus sham treatment. CI, Confidence interval.

active sessions following the initial course of 15 tDCS sessions.

Is active tDCS associated with a significant reduction in symptom severity compared with sham tDCS?

The pooled estimate of effect size (Hedges' g) for the reduction of depressive symptoms (as indicated by percentage reductions in severity score) between active and sham tDCS was 0.74 [$Z=2.76, p=0.006, 95\%$ confidence interval (CI) 0.21–1.27], indicating a significant medium to large effect size (Fig. 2). However, the test for heterogeneity was significant ($Q=15.5, df=6, p=0.017; I^2=61.4$), indicating that the variability in outcome measures between the studies exceeded that expected by chance. Measures of publication bias were significant with neither Begg and Mazumdar rank correlations (Kendall's $\tau=0.29, p=0.37$) nor Egger's regression intercept test (t value = 1.35, $p=0.24$) (Fig. 3). If the two significant Fregni studies not published as full papers are excluded, the equivalent figures are: Hedges' $g=0.42$ (95% CI 0.09–0.75), $Z=2.50, p=0.013$. In other words, the pooled effect size remained significant. While the heterogeneity of effect sizes, Q , was significant for all seven studies, it was no longer so for the five remaining studies ($Q=4.1, df=4, p=0.39$).

What possible predictors are there for treatment response?

Meta-regression with baseline symptom severity, concurrent antidepressant use, current strength and the total number of sessions did not reveal any significant correlations.

Discussion

Our systematic review indicated that active tDCS is associated with a reduction in symptom severity of approximately 29% and that the beneficial effects




Fig. 3. Funnel plot of standard error by Hedges' g.

persist at 1-month follow-up. However, there was a wide range in percentage reduction in severity score reported between studies, and only four studies reported 1-month follow-up data. The percentage of responders and remitters to treatment reported varied considerably between studies, presumably reflecting the degree of treatment resistance of the samples recruited and possibly differences in tDCS treatment parameters.

Our meta-analysis detected a significant reduction in symptom severity in active tDCS compared with sham conditions. Although Cochran's Q can be underpowered when analysis involves few studies, heterogeneity was significant. While meta-regression with possible sources of heterogeneity was not significant, this may be a result of the small number of studies included and the lack of availability of quantitative data on treatment resistance. Further, meta-regression was limited by 'missing data'; although authors were contacted regarding details not explicitly stated within their studies and several positive responses were received (detailed in Acknowledgements), it was not possible to obtain all outcome measures for all studies. Absence of homogeneous results suggests that no individually described protocol can be taken as paradigmatic for tDCS, i.e. can be claimed to generate the pooled effect size. Absence of homogeneity after meta-regression with likely confounders of treatment method suggests that patient sampling may be one of the major reasons for differing results and emphasizes the need for large-scale clinically representative trial samples.

Methodological considerations

There are limitations associated with performing a meta-analysis on a small number of studies, so our results need to be treated with caution. Results must be considered in the light of possible bias within studies and also variability in patient characteristics (concurrent medication, baseline severity score,

number of adequate, but unsuccessful antidepressant trials) and stimulation parameters (number and spacing of sessions, current strength, electrode site) between studies, which may influence outcome and result in significant heterogeneity.

An important possible source of bias within trials of tDCS of depression, especially open-label studies, is the placebo effect. While all RCTs included in the meta-analysis were double-blind, blinding success was only reported by three studies (Loo *et al.* 2010, 2012; Palm *et al.* 2011). All three studies did not find a significant difference between active and sham conditions and guesses. Across studies, it should be noted that research groups often reported multiple studies, although studies included in the meta-analysis did not contain overlapping participants.

Variability in patient population is a key factor that may have contributed to differences in outcomes between studies. As it has been repeatedly noted that the effects of tDCS are influenced substantially by neuro-modulators including dopamine and acetylcholine (Nitsche *et al.* 2004, 2009; Kuo *et al.* 2007, 2008), a crucial question is whether the efficacy of tDCS is influenced by the current medication status of patients. In this review, the medication status of patients varied both between and within studies. For example, all patients included in Boggio *et al.* (2008) and Fregni *et al.* (2006a, b) had not received antidepressant medication for at least 2 (Boggio *et al.* 2008) or 3 (Fregni *et al.* 2006a) months before tDCS, and remained antidepressant-free for the duration of tDCS treatment. In contrast, the studies performed by Loo *et al.* (Loo *et al.* 2010, 2012; Martin *et al.* 2011) and Palm *et al.* (2011) included both antidepressant-free patients and patients receiving antidepressant treatment. Medication had been stable for at least 3 weeks (Palm *et al.* 2011) or 4 weeks (Loo *et al.* 2010, 2012) prior to tDCS treatment, and was maintained throughout the course of tDCS. As participants had failed to respond to antidepressant treatment, and as concurrent antidepressant use would affect active and sham groups similarly, concurrent antidepressant treatment was unlikely to enhance results in these studies. However, it is still possible that it is the interaction between tDCS and medication that caused the treatment response. A meta-analysis of rTMS in the treatment of depression found that rTMS was more effective when used in monotherapy, rather than as an adjunctive to antidepressant treatment (Slotema *et al.* 2010). Meta-regression with concurrent antidepressant use was not significant; however, this result cannot be interpreted as conclusive. There were insufficient data available to systematically investigate the effect of other concurrent medications (e.g. anti-convulsants, benzodiazepines, lithium salts, anti-psychotics),

but these were noted in some studies included in the meta-analysis (Boggio *et al.* 2008; Palm *et al.* 2011).

The efficacy of tDCS in the treatment of depression may also vary with baseline symptom severity. Meta-regression with baseline severity score did not reveal a significant correlation with effect size, and Boggio *et al.* (2008) also did not detect a significant relationship within their sample. Only one study to date has included separate groups of mild-moderate and severe depression (Ferrucci *et al.* 2009). A significant reduction of depressive symptoms in patients at 1-month follow-up was only noted for the group of patients with severe depression.

Variability in the stimulation parameters used in the studies included is a second important consideration. Meta-regression with current strength and number of tDCS sessions did not identify any significant relationships with effect size. However, regression analysis is limited as it examines each parameter separately and not the combination of parameters employed. Frequency of sessions may also make an impact upon outcome, with Alonzo *et al.* (2011) reporting that daily tDCS leads to greater increases in cortical excitability than second daily tDCS. Further large-scale studies are needed to systematically investigate optimal treatment parameters.

It is not yet certain which specific brain areas should be targeted with tDCS to achieve optimal treatment efficacy. The rationale behind electrode placement in many of the early studies was stimulation of the brainstem, and for this reason anodal electrodes were placed as close as possible to the eyebrows. However, it is possible that cortical, mid-brain or diencephalic stimulation was at least partly responsible for the effects of tDCS in these early studies (Priori, 2003). Moreover, taking into account current knowledge about pathological alterations in depression, it is unclear if brainstem modulation can affect depressive symptoms. The majority of recent studies have employed a bi-frontal montage, in which the cathode is placed over a contralateral frontal area, and results in a focal frontal stimulation. An alternative approach is a fronto-extracerebral (F-EX) montage in which the cathode is placed over the right upper arm. This is hypothesized to result in a more widespread pattern of activation compared with a bi-frontal montage. Martin *et al.* (2011) performed F-EX tDCS in 11 participants who had previously shown inadequate response to, or relapsed, following a course of bi-frontal tDCS. F-EX tDCS resulted in a significant reduction in depressive symptoms, with participants displaying greater initial treatment responses with F-EX tDCS than with bi-frontal tDCS.

tDCS risks and safety

The most frequently reported side-effects within studies included in the systematic review were headache, itchiness and redness at the site of the stimulation (Boggio *et al.* 2008; Loo *et al.* 2010, 2012; Palm *et al.* 2011), with side-effects reported in both active and sham groups. Palm *et al.* (2008) also reported several cases of skin lesions. However, after physiological saline solution was used for electrode preparation rather than tap water, no further skin lesions were observed (Palm *et al.* 2011). tDCS can be reliably given without causing skin lesions with careful attention to stimulation technique (Loo *et al.* 2011). tDCS was reported to be well tolerated in all other studies (Fregni *et al.* 2006a, b; Ferrucci *et al.* 2009; Brunoni *et al.* 2011b; Dell'Osso *et al.* 2011; Martin *et al.* 2011).

Such findings are in line with a recent systematic review of adverse effects that found that the most common adverse effects reported in 172 tDCS studies were itching, tingling, headache, burning sensation and discomfort. Although adverse effects were more frequently reported with active tDCS, the difference was not statistically significant and there was a selective bias for reporting, assessing and publishing adverse effects (Brunoni *et al.* 2011a). Brunoni *et al.* (2011a) therefore propose a revised adverse effects questionnaire, which should be employed by future studies of tDCS in depression.

Three studies reported induction of a hypomanic episode during treatment with tDCS (Loo *et al.* 2010, 2012; Martin *et al.* 2011), with two detailed as case-reports (Arul-Anandam *et al.* 2010; Galvez *et al.* 2011). A further case-report of hypomania (Baccaro *et al.* 2010) has been detailed in an ongoing clinical trial of tDCS for depression (Brunoni *et al.* 2011c).

Conclusions

In conclusion, this review indicates that tDCS has potential as an effective clinical treatment for depression. However, our study was limited by the small number of studies included, which often had small sample size. Also, studies included in our review varied in sample characteristics and treatment parameters, both of which have the potential to influence the results of individual studies. Further large-scale studies in representative health service patient samples are needed to identify the optimal treatment parameters systematically. Additionally, studies with longer follow-up times are required, in order to explore whether antidepressant effects are lasting or if maintenance treatment is necessary.

Note

Supplementary material accompanies this paper on the Journal's website (<http://journals.cambridge.org/psm>).

Acknowledgements

Many thanks to Drs Alzono, Boggio, Ferrucci, Fregni, Palm and Priori for supplying additional data. U.G.K. and C.E.S. were funded by the Gordon Small Charitable Trust (Scottish Charity Register no. SC008962).

Declaration of Interest

None.

References

- Alonzo A, Brassil J, Taylor JL, Martin D, Loo CK (2011). Daily transcranial direct current stimulation (tDCS) leads to greater increases in cortical excitability than second daily transcranial direct current stimulation. *Brain Stimulation*. Published online 25 May 2011. doi:10.1016/j.brs.2011.04.006.
- Arfai E, Theano G, Montagu JD, Robin AA (1970). A controlled study of polarization in depression. *British Journal of Psychiatry* **116**, 433–434.
- Arul-Anandam AP, Loo C, Mitchell P (2010). Induction of hypomanic episode with transcranial direct current stimulation. *Journal of ECT* **26**, 68–69.
- Baccaro A, Brunoni AR, Bensenor IM, Fregni F (2010). Hypomanic episode in unipolar depression during transcranial direct current stimulation. *Acta Neuropsychiatrica* **22**, 316–318.
- Baker AP (1970). Brain stem polarization in the treatment of depression. *South African Medical Journal* **44**, 473–475.
- Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. *Biometrics* **50**, 1088–1101.
- Bindman LJ, Lippold OCJ, Redfearn JW (1964). The action of brief polarizing currents on cerebral cortex of the rat (1) during current flow and (2) in production of long-lasting after-effects. *Journal of Physiology* **172**, 369–382.
- Boggio PS, Rigonatti SP, Ribeiro RB, Myczkowski ML, Nitsche MA, Pascual-Leone A, Fregni F (2008). A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression. *International Journal of Neuropsychopharmacology* **11**, 249–254.
- Brunoni AR, Amadera J, Berbel B, Volz MS, Rizzerio BG, Fregni F (2011a). A systematic review on reporting and assessment of adverse effects associated with transcranial direct current stimulation. *International Journal of Neuropsychopharmacology* **14**, 1133–1145.
- Brunoni AR, Ferrucci R, Bortolomasi M, Vergari M, Tadini L, Boggio PS, Giacomuzzi M, Barbieri S, Priori A

- (2011b). Transcranial direct current stimulation (tDCS) in unipolar vs. bipolar depressive disorder. *Progress in Neuropsychopharmacology and Biological Psychiatry* 35, 96–101.
- Brunoni AR, Valiengo L, Baccaro A, Zanao TA, de Oliveira JF, Vieira GP, Bueno VF, Goulart AC, Boggio PS, Lotufo PA, Bensenor IM, Fregni F** (2011c). Sertraline vs. Electrical Current Therapy for Treating Depression Clinical Trial – SELECT TDCS: design, rationale and objectives. *Contemporary Clinical Trials* 32, 90–98.
- Carney MW, Cashman MD, Sheffield BF** (1970). Polarization in depression. *British Journal of Psychiatry* 117, 474–475.
- Costain R, Redfeam JW, Lippold OCJ** (1964). Controlled trial of therapeutic effects of polarization of brain depressive-illness. *British Journal of Psychiatry* 110, 786–799.
- Dell’Osso B, Zanoni S, Ferrucci R, Vergari M, Castellano F, D’Urso N, Dobrea C, Benatti B, Arici C, Priori A, Altamura AC** (2011). Transcranial direct current stimulation for the outpatient treatment of poor-responder depressed patients. *European Psychiatry*. Published online 27 May 2011. doi:10.1016/j.eurpsy.2011.02.008.
- Egger M, Davey Smith G, Schneider M, Minder C** (1997). Bias in meta-analysis detected by a simple, graphical test. *British Medical Journal* 315, 629–634.
- Ferrucci R, Bortolomasi M, Brunoni A, Vergari M, Tadini L, Giacomuzzi M, Priori A** (2009). Comparative benefits of transcranial direct current stimulation (TDCS). Treatment in patients with mild/moderate vs. severe depression. *Clinical Neuropsychiatry* 6, 246–251.
- Fregni F, Boggio PS, Nitsche MA, Marcolin MA, Rigonatti SP, Pascual-Leone A** (2006a). Treatment of major depression with transcranial direct current stimulation. *Bipolar Disorders* 8, 203–204.
- Fregni F, Boggio PS, Nitsche MA, Rigonatti SP, Pascual-Leone A** (2006b). Cognitive effects of repeated sessions of transcranial direct current stimulation in patients with depression. *Depression and Anxiety* 23, 482–484.
- Galvez V, Alonzo A, Martin D, Mitchell PB, Sachdev P, Loo CK** (2011). Hypomania induction in a patient with bipolar II disorder by transcranial direct current stimulation (tDCS). *Journal of ECT* 27, 256–258.
- Grimm S, Beck J, Schuepbach D, Hell D, Boesiger P, Bempohl F, Niehaus L, Boeker H, Northoff G** (2008). Imbalance between left and right dorsolateral prefrontal cortex in major depression is linked to negative emotional judgment: an fMRI study in severe major depressive disorder. *Biological Psychiatry* 63, 369–376.
- Hedges D, Vevea J** (1998). Fixed- and random-effects models in meta-analysis. *Psychological Methods* 3, 486–504.
- Heo M, Murphy CF, Meyers BS** (2007). Relationship between the Hamilton Depression Rating Scale and the Montgomery–Asberg Depression Rating Scale in depressed elderly: a meta-analysis. *American Journal of Geriatric Psychiatry* 15, 899–905.
- Higgins JP, Thompson SG, Deeks JJ, Altman DG** (2003). Measuring inconsistency in meta-analyses. *British Medical Journal* 327, 557–560.
- Koenigs M, Ukueberuwa D, Campion P, Grafman J, Wassermann E** (2009). Bilateral frontal transcranial direct current stimulation: failure to replicate classic findings in healthy subjects. *Clinical Neurophysiology* 120, 80–84.
- Kuo MF, Grosch J, Fregni F, Paulus W, Nitsche MA** (2007). Focusing effect of acetylcholine on neuroplasticity in the human motor cortex. *Journal of Neuroscience* 27, 14442–14447.
- Kuo MF, Paulus W, Nitsche MA** (2008). Boosting focally-induced brain plasticity by dopamine. *Cerebral Cortex* 18, 648–651.
- Lippold OCJ, Redfeam JW** (1964). Mental changes resulting from passage of small direct currents through human brain. *British Journal of Psychiatry* 110, 768–772.
- Loo C, Martin D, Alonzo A, Gandevia S, Mitchell P, Sachdev P** (2011). Avoiding skin burns with transcranial direct current stimulation: preliminary considerations. *International Journal of Neuropsychopharmacology* 14, 425–426.
- Loo CK, Alonzo A, Martin D, Mitchell P, Galvez V, Sachdev P** (2012). A three-week, randomized, sham-controlled trial of transcranial direct current stimulation in depression. *British Journal of Psychiatry* 200, 1–8. doi:10.1192/bjp.bp.111.097634.
- Loo CK, Sachdev P, Martin D, Pigot M, Alonzo A, Malhi GS, Lagopoulos J, Mitchell P** (2010). A double-blind, sham-controlled trial of transcranial direct current stimulation for the treatment of depression. *International Journal of Neuropsychopharmacology* 13, 61–69.
- Martin DM, Alonzo A, Mitchell PB, Sachdev P, Galvez V, Loo CK** (2011). Fronto-extracerebral transcranial direct current stimulation as a treatment for major depression: an open-label pilot study. *Journal of Affective Disorders* 134, 459–463.
- Nias DK, Shapiro MB** (1974). The effects of small electrical currents upon depressive symptoms. *British Journal of Psychiatry* 125, 414–415.
- Nitsche MA, Boggio PS, Fregni F, Pascual-Leone A** (2009). Treatment of depression with transcranial direct current stimulation (tDCS): a review. *Experimental Neurology* 219, 14–19.
- Nitsche MA, Fricke K, Henschke U, Schlitterlau A, Liebetanz D, Lang N, Henning S, Tergau F, Paulus W** (2003). Pharmacological modulation of cortical excitability shifts induced by transcranial direct current stimulation in humans. *Journal of Physiology* 553, 293–301.
- Nitsche MA, Niehaus L, Hoffmann KT, Hengst S, Liebetanz D, Paulus W, Meyer BU** (2004). MRI study of human brain exposed to weak direct current stimulation of the frontal cortex. *Clinical Neurophysiology* 115, 2419–2423.
- Nitsche MA, Paulus W** (2000). Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. *Journal of Physiology* 527, 633–639.
- Nitsche MA, Paulus W** (2001). Sustained excitability elevations induced by transcranial DC motor cortex stimulation in humans. *Neurology* 57, 1899–1901.
- Palm U, Keeser D, Schiller C, Fintescu Z, Nitsche M, Reisinger E, Padberg F** (2008). Skin lesions after treatment with transcranial direct current stimulation (tDCS). *Brain Stimulation* 1, 386–387.

- Palm U, Schiller C, Fintescu Z, Obermeier M, Keeser D, Reisinger E, Pogarell O, Nitsche MA, Möller HJ, Padberg F** (2011). Transcranial direct current stimulation in treatment resistant depression: a randomized double-blind, placebo-controlled study. *Brain Stimulation*. Published online 7 September 2011. doi:10.1016/j.brs.2011.08.005.
- Priori A** (2003). Brain polarization in humans: a reappraisal of an old tool for prolonged non-invasive modulation of brain excitability. *Clinical Neurophysiology* **114**, 589–595.
- Priori A, Berardelli A, Rona S, Accornero N, Manfredi M** (1998). Polarization of the human motor cortex through the scalp. *Neuroreport* **9**, 2257–2260.
- Ramsay JC, Schlagenhauf G** (1966). Treatment of depression with low voltage direct current. *Southern Medical Journal* **59**, 932–934.
- Redfean JW, Costain R, Lippold OCJ** (1964). Preliminary account of clinical effects of polarizing brain in certain psychiatric disorders. *British Journal of Psychiatry* **110**, 773–785.
- Slotema CW, Blom JD, Hoek HW, Sommer IE** (2010). Should we expand the toolbox of psychiatric treatment methods to include repetitive transcranial magnetic stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. *Journal of Clinical Psychiatry* **71**, 873–884.